Form 4: Oruka Therapeutics President Sells Shares
Insider Transaction (Form 4)
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 10,000 shares of common stock on August 13, 2026.
Summary
- Option exercise/conversion: acquired 8,542 Common Stock at $12.50 ($106,775) on August 13, 2026; holds 23,854 after (Direct).
- Option exercise/conversion: acquired 1,458 Common Stock at $34.39 ($50,141) on August 13, 2026; holds 25,312 after (Direct).
- Open-market sale: disposed of 2,100 Common Stock at $104.67 ($219,814) on August 13, 2026; holds 23,212 after (Direct).
- Open-market sale: disposed of 2,132 Common Stock at $105.57 ($225,079) on August 13, 2026; holds 21,080 after (Direct).
- Open-market sale: disposed of 1,268 Common Stock at $106.63 ($135,201) on August 13, 2026; holds 19,812 after (Direct).
- Open-market sale: disposed of 2,142 Common Stock at $107.71 ($230,723) on August 13, 2026; holds 17,670 after (Direct).
- Open-market sale: disposed of 2,358 Common Stock at $108.46 ($255,755) on August 13, 2026; holds 15,312 after (Direct).
- Option exercise/conversion: disposed of 8,542 Employee Stock Option (right to buy) on August 13, 2026; holds 92,917 after (Direct).
- Option exercise/conversion: disposed of 1,458 Employee Stock Option (right to buy) on August 13, 2026; holds 59,792 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,066,572 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Arjun Agarwal — Officer (Senior Vice President, Finance)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-13 | Option exercise/conversion | Common Stock | 8,542 | $13 | $106.8K | 23,854 |
| 2026-08-13 | Option exercise/conversion | Common Stock | 1,458 | $34 | $50.1K | 25,312 |
| 2026-08-13 | Open-market sale | Common Stock | 2,100 | $105 | $219.8K | 23,212 |
| 2026-08-13 | Open-market sale | Common Stock | 2,132 | $106 | $225.1K | 21,080 |
| 2026-08-13 | Open-market sale | Common Stock | 1,268 | $107 | $135.2K | 19,812 |
| 2026-08-13 | Open-market sale | Common Stock | 2,142 | $108 | $230.7K | 17,670 |
| 2026-08-13 | Open-market sale | Common Stock | 2,358 | $108 | $255.8K | 15,312 |
| 2026-08-13 | Option exercise/conversion | Employee Stock Option (right to buy) | 8,542 | — | — | 92,917 |
| 2026-08-13 | Option exercise/conversion | Employee Stock Option (right to buy) | 1,458 | — | — | 59,792 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-13 | Option exercise/conversion (8,542 shares) |
| 2026-08-13 | Option exercise/conversion (1,458 shares) |
| 2026-08-13 | Open-market sale (2,100 shares) |
| 2026-08-13 | Open-market sale (2,132 shares) |
| 2026-08-13 | Open-market sale (1,268 shares) |
| 2026-08-13 | Open-market sale (2,142 shares) |
| 2026-08-13 | Open-market sale (2,358 shares) |
| 2026-08-13 | Option exercise/conversion (8,542 shares) |
| 2026-08-13 | Option exercise/conversion (1,458 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Arjun Agarwal
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.